VEON Ltd. has agreed to acquire Rubicon Wireless, operating as Perfectum in Uzbekistan, for about $207 million including debt. This acquisition expands Beeline Uzbekistan's spectrum by 50%, enhancing its 4G/LTE network and paving the way for 5G and fixed wireless services. The deal strengthens VEON's position in Uzbekistan's telecom market, supporting digital growth and improved connectivity for nearly 40 million people. Completion is expected by the end of October after regulatory approvals.
VEON's $207 million acquisition of Rubicon Wireless in Uzbekistan is a major telecom market move. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 19, 2026 16:11 WIB: Among 150 priced Technology-sector US stocks tradable on Pluang, 110 rose and 18 fell today. Notable gainers include AXTI at USD 53.81 (+4.55%), BTDR at USD 8.06 (+4.40%), and INTC at USD 93.32 (+3.86%), with typical hold times ranging from 16 to 117 days.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
